.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Julphar
Merck
Teva
Healthtrust
Cantor Fitzgerald
Cipla
Queensland Health
Federal Trade Commission

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,579,865

« Back to Dashboard

Which drugs does patent 8,579,865 protect, and when does it expire?


Patent 8,579,865 protects OTREXUP and is included in one NDA.

This patent has twelve patent family members in seven countries.

Summary for Patent: 8,579,865

Title:Hazardous agent injection system
Abstract: Injection systems comprising a powered injector and one or more hazardous agents are disclosed.
Inventor(s): Wotton; Paul (Stamford, CT), Sadowski; Peter L. (Woodbury, MN), Hayes; John William (Chaska, MN)
Assignee: Antares Pharma, Inc. (Ewing, NJ)
Application Number:13/257,555
Patent Claim Types:
see list of patent claims
Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-005Nov 7, 2014DISCNNoNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-001Oct 11, 2013RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-006Mar 24, 2016RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-002Oct 11, 2013RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-007Mar 24, 2016RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-003Oct 11, 2013RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-008Mar 24, 2016RXYesNo► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
Antares Pharma IncOTREXUPmethotrexateSOLUTION;SUBCUTANEOUS204824-004Oct 11, 2013RXYesYes► Subscribe► Subscribe► SubscribeYSUBCUTANEOUS INJECTION OF METHOTREXATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,579,865

PCT Information
PCT FiledMarch 19, 2010PCT Application Number:PCT/US2010/028011
PCT Publication Date:September 23, 2010PCT Publication Number: WO2010/108116

Non-Orange Book Patents for Patent: 8,579,865

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,480,631Hazardous agent injection system► Subscribe
9,750,881Hazardous agent injection system► Subscribe
9,421,333Hazardous agent injection system► Subscribe
8,945,063Hazardous agent injection system► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,579,865

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
South Korea101597672► Subscribe
South Korea20120028294► Subscribe
Japan2016104214► Subscribe
Japan5968976► Subscribe
Japan2015042270► Subscribe
Japan5732039► Subscribe
Japan2012521224► Subscribe
European Patent Office2408493► Subscribe
China102612381► Subscribe
Canada2755779► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
AstraZeneca
Cantor Fitzgerald
Farmers Insurance
Cipla
UBS
McKinsey
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot